Scar – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Scar
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This latest pipeline guide Scar – Pipeline Review, H1 2019,
provides comprehensive information on the therapeutics under development
for Scar (Dermatology), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players
involved in therapeutic development for Scar and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies/Universities/Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I and Preclinical stages are 1,
5, 1 and 9 respectively. Similarly, the Universities portfolio in Phase
I and Preclinical stages comprises 1 and 2 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Scar (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Scar
  (Dermatology) by companies and universities/research institutes based
  on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Scar
  (Dermatology) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Scar (Dermatology) therapeutics based on
  mechanism of action (MoA), drug target, route of administration (RoA)
  and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Scar (Dermatology).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Scar (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Involved in Therapeutics Development

• Abzena PLC
• BirchBioMed Inc.
• Cotinga Pharmaceuticals Inc.
• Kringle Pharma Inc.
• Moerae Matrix Inc.
• Pharmaxis Ltd.
• Phio Pharmaceuticals Corp.
• Promore Pharma AB
• Resolys Bio Inc.
• Synedgen Inc.
• Vascular BioSciences

Drug Profiles

• albuterol
• BTL-slo
• decorin
• Evitar
• FBM-5712
• FS-2
• Fusion Protein for Scar
• ICX-RHY
• KP-100IT
• magacizumab
• MG-53
• MMI-0100
• Monoclonal Antibody for Fibrotic Scar
• nefopam hydrochloride
• Polysaccharide for Wounds and Scars
• PXL-01
• RXI-109
• Small Molecule to Inhibit Lysyl Oxidase for Scar and Oncology
• Small Molecules to Inhibit SOX-9 for Scar

Featured News & Press Releases

• Feb 28, 2019: First patient enrolled in BirchBioMed’s study
  investigating FS2 for the treatment of scars
• Feb 01, 2019: Promore Pharma modifies its Phase III trial of PXL01 and
  expands the number of clinics in the study
• Oct 23, 2018: Promore Pharma has had a successful meeting with the FDA
  regarding PXL01
• Sep 03, 2018: Promore Pharma plans to expand indications of
  therapeutic peptide PXL01 in the field of dermal scarring
• May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology
  Intellectual Property Estate Following Granting of Patent From USPTO
• Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase
  II clinical trial for ground-breaking anti-scarring drug
• Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing
• Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US
• Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America
• Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from
  Phase 2 Trial with RXI-109 for Dermal Scarring
• Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction
  Trial Safety and Efficacy Results Targeted for Late 2017
• May 17, 2017: Promore Pharma files phase III clinical trial
  application in India
• Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead
  Clinical Candidate RXI-109
• Aug 25, 2016: BirchBioMed announces completion of clinical trial for
  ground-breaking anti-scarring drug
• Aug 18, 2016: ScarX announces approval for trial of first
  clinically-promising scar reduction cream

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8vd8d7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Dermatological
Drugs